{"name":"Ionis Pharmaceuticals, Inc.","slug":"ionis-pharmaceuticals-inc","ticker":"","exchange":"","domain":"ionispharma.com","description":"","hq":"Carlsbad","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":203330000,"revenueGrowth":-10.3,"grossMargin":0,"rdSpend":915619000,"netIncome":-381387000,"cash":3523836000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"cardiovascular","drugs":[{"name":"ISIS-GCGRRx","genericName":"ISIS-GCGRRx","slug":"isis-gcgrrx","indication":"Other","status":"phase_2"},{"name":"APOC-III-L-Rx","genericName":"APOC-III-L-Rx","slug":"apoc-iii-l-rx","indication":"Other","status":"phase_1"},{"name":"BIIB094","genericName":"BIIB094","slug":"biib094","indication":"Other","status":"phase_1"},{"name":"IONIS GHR-LRx","genericName":"IONIS GHR-LRx","slug":"ionis-ghr-lrx","indication":"Acromegaly","status":"phase_2"},{"name":"IONIS-DMPKRx","genericName":"IONIS-DMPKRx","slug":"ionis-dmpkrx","indication":"Other","status":"phase_1"},{"name":"ISIS 443139 10 mg","genericName":"ISIS 443139 10 mg","slug":"isis-443139-10-mg","indication":"Other","status":"phase_1"},{"name":"ISIS 443139 90 mg","genericName":"ISIS 443139 90 mg","slug":"isis-443139-90-mg","indication":"Other","status":"phase_1"},{"name":"ISIS apoC-III Rx","genericName":"ISIS apoC-III Rx","slug":"isis-apoc-iii-rx","indication":"Hypertriglyceridemia","status":"phase_2"},{"name":"ISIS-FXIRx Dose #2","genericName":"ISIS-FXIRx Dose #2","slug":"isis-fxirx-dose-2","indication":"Other","status":"phase_2"},{"name":"ISIS-GCCRRx","genericName":"ISIS-GCCRRx","slug":"isis-gccrrx","indication":"Other","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ION363","genericName":"ION363","slug":"ion363","indication":"Hypertriglyceridemia in patients at high cardiovascular risk","status":"phase_3"},{"name":"ION582","genericName":"ION582","slug":"ion582","indication":"Hypercholesterolemia; LDL cholesterol reduction in patients at high cardiovascular risk","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ISIS-FGFR4RX","genericName":"ISIS-FGFR4RX","slug":"isis-fgfr4rx","indication":"Solid tumors","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"ISIS-PTP1BRx","genericName":"ISIS-PTP1BRx","slug":"isis-ptp1brx","indication":"Type 2 diabetes mellitus","status":"phase_2"}]}],"pipeline":[{"name":"ION363","genericName":"ION363","slug":"ion363","phase":"phase_3","mechanism":"ION363 is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III), a protein that impairs triglyceride clearance and increases cardiovascular risk.","indications":["Hypertriglyceridemia in patients at high cardiovascular risk"],"catalyst":""},{"name":"ISIS-FGFR4RX","genericName":"ISIS-FGFR4RX","slug":"isis-fgfr4rx","phase":"phase_2","mechanism":"Antisense oligonucleotide targeting fibroblast growth factor receptor 4","indications":["Solid tumors"],"catalyst":""},{"name":"ISIS-GCGRRx","genericName":"ISIS-GCGRRx","slug":"isis-gcgrrx","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"APOC-III-L-Rx","genericName":"APOC-III-L-Rx","slug":"apoc-iii-l-rx","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BIIB094","genericName":"BIIB094","slug":"biib094","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ION582","genericName":"ION582","slug":"ion582","phase":"phase_3","mechanism":"ION582 is an antisense oligonucleotide that reduces production of apolipoprotein B (ApoB) to lower LDL cholesterol levels.","indications":["Hypercholesterolemia; LDL cholesterol reduction in patients at high cardiovascular risk"],"catalyst":""},{"name":"IONIS GHR-LRx","genericName":"IONIS GHR-LRx","slug":"ionis-ghr-lrx","phase":"phase_2","mechanism":"IONIS GHR-LRx is an antisense oligonucleotide that inhibits growth hormone receptor (GHR) expression to reduce growth hormone signaling.","indications":["Acromegaly"],"catalyst":""},{"name":"IONIS-DMPKRx","genericName":"IONIS-DMPKRx","slug":"ionis-dmpkrx","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ISIS 443139 10 mg","genericName":"ISIS 443139 10 mg","slug":"isis-443139-10-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ISIS 443139 90 mg","genericName":"ISIS 443139 90 mg","slug":"isis-443139-90-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ISIS apoC-III Rx","genericName":"ISIS apoC-III Rx","slug":"isis-apoc-iii-rx","phase":"phase_2","mechanism":"Antisense oligonucleotide that targets apolipoprotein C-III","indications":["Hypertriglyceridemia"],"catalyst":""},{"name":"ISIS-FXIRx Dose #2","genericName":"ISIS-FXIRx Dose #2","slug":"isis-fxirx-dose-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ISIS-GCCRRx","genericName":"ISIS-GCCRRx","slug":"isis-gccrrx","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ISIS-PTP1BRx","genericName":"ISIS-PTP1BRx","slug":"isis-ptp1brx","phase":"phase_2","mechanism":"ISIS-PTP1BRx is an antisense oligonucleotide that inhibits protein tyrosine phosphatase 1B (PTP1B) to improve insulin signaling and glucose metabolism.","indications":["Type 2 diabetes mellitus","Obesity"],"catalyst":""}],"recentEvents":[],"realNews":[{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOZFJWX2d5WWxwaXpDek95WGJjNVE5cnBpMnVRT01QQWcyM2ZRQUd2OW5kUnBYb0NWdEQ3QVRhZ1JhOTJhZ2Nyb0o2dDRhaUZoS0U2RE1Rc3A5VXhnXzNWQk82WjllZk1pZWRQOWNxT1E5MzR2WUVqcjZNY2xfRVFlLUl5TkFPQWlib1c1Q0o0elBjSnFwTmc0enM4ZFptcm9uMy1sWGZINGkwOHk0SUpjTzNKSHo?oc=5","date":"2025-12-19","type":"pipeline","source":"Investing.com","summary":"cathie wood’s ARK stock trades highlight ionis pharma sale - Investing.com","headline":"cathie wood’s ARK stock trades highlight ionis pharma sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxPRWNfY2xLRHdNeVg1UXd5aktOU2JXdUpISFR4akdDN0ZiR2NEOWZrQnZkNGg1Zl9MbklMRmw2UngyWGUzVVVweFVQSk84VUQyMVZTY1ZMMFk4d2xLMzJlSXVjbm5MV090YnFQZ1hudnE5eUs3aTVWUmRnN1hORl9tRi1BTkx4YU5COG9CaXZqYnhmcEFwNm1QSGJUdkVJdkctcjZaWlNValkxcTkwdjJqTjFOb1g4NXpMcHZncy0ya29nZjJxX2loUEliV2c2cy1JZGJSTmVMVDNTQlBPSGRiVXUxcF9iX2J6b1R1a1JQOVBzYkZQQThMQm04SlFQQjl3S2RMekFyRENnRTlUMlQzdWZfWXpHbzJfXzVJa04xNERhRHU4eVlxSnl2a2taWGNjYWtJaFlIV2lOdnZTeVhaRmdlWXBGaHNPSDFRczNwc2xsRndBX0lB?oc=5","date":"2025-12-15","type":"regulatory","source":"businesswire.com","summary":"GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe - businesswire.com","headline":"GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOUTdDQk5HZkhVcnFNNjM4TE5nWWNvd25pQkh5VF95SS1qd2JrMnhnUUpUQ2FsZVl4aWUwRjNZenVMMkh4bWM2SENGdERiT19veXNRUEJrNDhScDV1UzNVRU9sa1dGY0prOTJVSW93aEptVGN6QkFPNHpOUEZubFhHY0xtakNQSjYyX1VzS3JqTGtmQWFYSHJtdnl0NWw0bjMzbFFFcXZHUW1fMi1GNEg5M1lhbHlUMHBHUnc?oc=5","date":"2025-10-01","type":"pipeline","source":"GuruFocus","summary":"Insider Sell: Patrick O'neil Sells 25,300 Shares of Ionis Pharma - GuruFocus","headline":"Insider Sell: Patrick O'neil Sells 25,300 Shares of Ionis Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBtcXRkVXRSenlXZFdxUWR1V0drMWlTeUNfUVBQRERlUV9qeVdoTEo3LXhyRWRBYVdxZ2VocVMxTVB2cm5JWVE3Q1ZscUJIdHlKSEdQaU5DSDVqOUctTE5fVWc0b0tCVm16aGR1S3Z1ODY1cGV6?oc=5","date":"2025-09-30","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Top pharmaceuticals of H1 2025: Ozempic and Mounjaro enter top three - drugdiscoverytrends.com","headline":"Top pharmaceuticals of H1 2025: Ozempic and Mounjaro enter top three","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPWDBYSnJlU2d0djlXMFBuYnp1eUJnblFlelZUVFlkMlNpY1U5WElDZHdUbzc2cnpadV9QaG5Gdl9kRUd5M0lQMHlXanQ2RzZoMVlMWkY5WTg0eUtCdGl4SURlWEoyQTNTMzZ4WHN5SkpnbWtZN21tR0lRaDNOeHk1eHd1a1hmOVpsWDVURjVFWXhEMzFENjRmWjBfOFVBTTZfUmVxSHhIMzB4VUp4WlVaRk5ka3BLdzJuR1Qtcg?oc=5","date":"2025-09-23","type":"regulatory","source":"MedCity News","summary":"Ionis Pharma’s Drug for Rare Disease With No Approved Therapies Meets Goals of Pivotal Study - MedCity News","headline":"Ionis Pharma’s Drug for Rare Disease With No Approved Therapies Meets Goals of Pivotal Study","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOMlFDZklkaDEybjcyWDdqbGxRNXQtMDVvMVBXcnZiNkNsUGZiRFlncXFlRGk5a255a1cxX0ZRc29fQTRRZmVSZG0zekhQbFRzcHdZTG5ZTHBHOE1TSjJJQTAteFpZUmlHb3ZmdE1RbDVEcmpvbEducVk5WThBNWdWc214ejVfcG5LUjY1NDJ4bjlTdlFBSVlYTmlNZjI4TkY0SW4wZHZsWWJ4WXlFbkJFUVBGM1QwTjFFUWhqZWdQUUFxVGVQNkNN?oc=5","date":"2025-09-11","type":"pipeline","source":"Arrowhead Pharmaceuticals, Inc.","summary":"Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals - Arrowhead Pharmaceuticals, Inc.","headline":"Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals - Arrowhead Pharmaceuti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9nYXc3elUyb0VHeXRNelpSU1lMM2YwOG5QX1pyZ0lMVDZ6TGdlUjdMaFl5YXNWd2FVU2d4LWRjc25ydVVkdGxocWFFT2d6US13TlllZHJGcEc2X1FxdVFGRWVtaWkwNk1lRkJQYy1GRS0zVEJqdHRIalFIeHlnZw?oc=5","date":"2025-09-04","type":"pipeline","source":"Yahoo Finance","summary":"Ionis Pharma (IONS) Hits New High Anew as Analyst Sees Blockbuster Potential for Olezarsen - Yahoo Finance","headline":"Ionis Pharma (IONS) Hits New High Anew as Analyst Sees Blockbuster Potential for Olezarsen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNR2NlQXUyMUJxbldtVVh0TGU3T19pZzFkYjd0M2NSVmtPQWVtYnJSZ3dOZ3doejRBNWFWS0x4WkljRk9sTmw2VFU1MHhqak1jcjhvTmtDTTZPemNIVC1FUW5LSVlldTRhU3NEVE9ndFFjZ19oaGY5VldtYmlWTklhYi04bTZZMi1TM2tibkFmdw?oc=5","date":"2025-09-02","type":"pipeline","source":"Yahoo Finance","summary":"Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction - Yahoo Finance","headline":"Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxQV3p0WXY5ZXdmOG1nQ0hYMFQyVWs2SDhvWjZYNm1XOGRBLXNPdzEtWGo5WTJvSVVRVi1icS05U1hQcUhGRGxGQWxxdF9qejJuWm1BYlRJT2dYaEVmTzkyclRQWllNSmVMSEZheW9TREtoQ05vTzUxQkdSSXE2UFFJOXNHSkNIU0RhU0szNVVTX1FIRU4zU1RLeWh6Q2d1LVZqRmIxNlJUZWFvSWplYWlWTjJoTW5DdnFYXy1Zc01QQzNiZmxSWVRjWU1ZQnFieE1sbDFwZG9JVGhOOVhZelpWM0ZMMXluU2VrdDBEVDliV0RyRmhZblVDREpvVkRhWGdhZTROUWZFaVlhM3FOWWJuRDZXemRkd21Tc2RDOEsxR3BHcW1saEItV1ZvUkxDendudDZBZHFwUlNCRzc2NVBCYmdrMzc?oc=5","date":"2025-08-28","type":"trial","source":"GlobeNewswire","summary":"Antisense Oligonucleotide Therapeutics Clinical Trial - GlobeNewswire","headline":"Antisense Oligonucleotide Therapeutics Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPbjRZajJtYzRTeTFUQmpwSl9UeFlPU2JnUVR3VEtxUlhuYXJoVUZLQ19xV0tlSWZXVm5PWXBVeDJyMzlrSVU0bEhuMU9TMmNZOGU3RUhLYWhGaEtmQU9SdXA0NkpYNXNER3NiUjlJYzYwUWlXZHFiOU1rU2dmS3hPcjdqWTJLd2ZtZTZMSDlJWUhJNFJxR0FyR3hlTWYyczBzcHhCS25uOEFKajhPNEVndHYwdU4wbzQ?oc=5","date":"2025-08-26","type":"regulatory","source":"Seeking Alpha","summary":"Ionis: Dawnzera Approval Kicks Off New Era For Strikingly Undervalued Pharma (NASDAQ:IONS) - Seeking Alpha","headline":"Ionis: Dawnzera Approval Kicks Off New Era For Strikingly Undervalued Pharma (NASDAQ:IONS)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5SaF94VEIzSjVfQ0EyMWEzR0RmZlNYNXdiOVc2clQ5WEV0dUVVSmZfQWhNa0JYTW9oRmh2dWkxWE5sTmRCTm52bXhjWDc5VkZQRG9v?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"IONS Stock Price, News & Analysis - Stock Titan","headline":"IONS Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxPTjU0ZW0tVG1yUlF1ZUZqb2JoU1NQNXpMcDhlQTYyVENtQmFpTXFmMUNuSGhRU3FKekxIT25CdVFSeTJCMWhsZ0FtdElnTF9CMF9sT0t0QlRFMXZ4eVk1dHZYNWtmamxvU0duT04yaWFUbVRwZWJPcVZTSDBETE1EN2h4aHZ5aG14eWJaa1BQM0JFRjV4SHFtVFBqSDlVb1g3UFBTUXY1T3Z4Qkt5RHh1SWhWOC1MeDBKeFhNU1B5aXV0VkhHNjZuV2F2UU9xS3ZXeWVteU1UQ1lfbi1oYWhUeEpUbTlrSHg5R01DOWxlUHY5RHVkcmNOVEJlUk9nNlU3RnhLam0yWnpCU0EwZ3BnU0hDZkJ2NklTMjdzY1MzcG02b2pUVUE?oc=5","date":"2023-01-09","type":"pipeline","source":"PR Newswire","summary":"Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness - PR Newswire","headline":"Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines","sentiment":"neutral"}],"patents":[],"drugCount":14,"phaseCounts":{"phase_3":2,"phase_2":7,"phase_1":5},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":203330000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":203330000,"period":"2025-12-31"},{"value":226577000,"period":"2024-12-31"},{"value":226577000,"period":"2024-12-31"},{"value":324505000,"period":"2023-12-31"},{"value":324505000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":915619000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-381387000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":3523836000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}